Google faces more backlash over health data privacy concerns

Google has been partnering up with healthcare industry titans over the last few years in data exchange contracts that continue to draw criticism, Business Insider reported.

While Google is able to promise access to its AI capabilities and predictive analyses, hospitals and health systems hand over patient information to help build these tools. These partnerships could potentially be very lucrative for Google in the future as AI is incorporated more into healthcare, Business Insider reported.

One recent partnership that drew criticism was between Google and Ascension, the nation’s second-largest health system. However, one patient from University of Chicago has sued Google over obtaining health data that could be identifiable. The lawsuit documents offer a glimpse into the contract between Google and University of Chicago.

Google was given de-identified patient information, but because of Google’s data on the data and time patients signed into health services, Google may be able to pair that information with people, Business Insider reported.

See the full story below:

 

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.